Indivior Pharmaceuticals, Inc. INDV Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Product | ||||||
| PERSERIS | $24M-29.4% | $23M-43.9% | $27M-36.5% | $29M-35.6% | $34M-20.0% | |
| Sublingual & other | $222M-7.5% | $226M-9.2% | $219M-15.0% | $229M-14.2% | $240M-12.6% | |
| SUBLOCADE | $912M+21.1% | $856M+13.2% | $798M+10.9% | $770M+12.2% | $753M+15.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Indivior Pharmaceuticals, Inc. break its business down?
- Indivior Pharmaceuticals, Inc. (INDV) reports net revenue by product across 3 parts — PERSERIS, Sublingual & other and SUBLOCADE. Each is extracted from the segment footnotes and tracked over time.
- Where does Indivior Pharmaceuticals, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Indivior Pharmaceuticals, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.